Related Experiment Video
Updated: Aug 13, 2026

In situ Subcellular Fractionation of Adherent and Non-adherent Mammalian Cells
Published on: July 24, 2010
Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type
1Forschungsschwerpunkt Angewandte Tumorvirologie, Deutsches Krebsforschungszentrum, Heidelberg, Germany.
Abstract:
Somatic mutations in the p53 tumor suppressor gene represent the single most common genetic alteration observed in human cancers. Interestingly, the great majority of malignant tumors of the cervix uteri contain wild-type p53 alleles together with the DNA of specific types of human papillomaviruses (HPVs), while the small portion of HPV-negative cervical carcinomas often carry alterations in the p53 tumor suppressor gene. Transcriptional activation of yet-undefined cellular regulatory genes has been implicated to play a key role for the tumor-suppressive activity of wild-type p53, as mutant p53 in general has lost the activity to stimulate p53-responsive reporter plasmids. The detection of DNA-binding-competent and transcriptionally active p53 protein in HeLa cervical carcinoma cells enabled us to investigate the in vivo effects of putative modulators on endogenous p53 function in cervical cancer cells. We show that the transcriptional stimulatory activity of HeLa cell p53 is strongly repressed by overexpression of E6 protein from oncogenic HPV type 16 (HPV16) but is not influenced by low-risk HPV6 E6. Similar to HPV16 E6, cellular oncoproteins such as mutant p53 or the product of the human mdm-2 gene also negatively interfere with p53-mediated transactivation in HeLa cells. Our findings indicate that, within a cervical cancer cell, the expression of E6 protein from high-risk HPV16, but not from low-risk HPV6, can lead to the same functional consequences as a mutation of the p53 gene. These results could provide a biochemical basis for the inverse correlation between the presence of HPV sequences and somatic mutations of the p53 gene in cervical carcinomas.
Insights
High-risk human papillomavirus (HPV) type 16 E6 protein represses wild-type p53 activity in cervical cancer cells, mimicking p53 mutations and explaining the inverse correlation between HPV and p53 mutations in cervical carcinomas.
Area of Science:
- Oncology
- Virology
- Molecular Biology
Background:
- Somatic mutations in the p53 tumor suppressor gene are common in human cancers.
- Cervical cancers often have wild-type p53 with human papillomaviruses (HPVs), while HPV-negative cancers frequently have p53 mutations.
- Wild-type p53's tumor-suppressive activity involves transcriptional activation of regulatory genes, which is lost in mutant p53.
Purpose of the Study:
- To investigate the in vivo effects of potential modulators on endogenous p53 function in cervical cancer cells.
- To determine if HPV E6 proteins influence p53 activity in cervical cancer cells.
Main Methods:
- Detection of DNA-binding-competent and transcriptionally active p53 protein in HeLa cervical carcinoma cells.
- Investigating the effects of overexpressed HPV16 E6, HPV6 E6, mutant p53, and mdm-2 on p53-mediated transactivation in HeLa cells.
Main Results:
- Overexpression of HPV16 E6 strongly repressed the transcriptional stimulatory activity of p53 in HeLa cells.
- Low-risk HPV6 E6 did not influence p53 activity.
- Cellular oncoproteins, including mutant p53 and mdm-2, also negatively interfered with p53 transactivation.
Conclusions:
- Expression of high-risk HPV16 E6 protein in cervical cancer cells leads to functional consequences similar to p53 gene mutation.
- This repression of wild-type p53 by HPV16 E6 provides a biochemical basis for the observed inverse correlation between HPV presence and p53 mutations in cervical carcinomas.
More Related Videos
Related Concept Videos
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
Inhibition of Cdk Activity
Mitogens and the Cell Cycle
Abnormal Proliferation
DNA Damage Can Stall the Cell Cycle

